176 related articles for article (PubMed ID: 32344898)
1. PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208.
Muñoz-Galván S; Rivero M; Peinado-Serrano J; Martinez-Pérez J; Fernández-Fernández MC; Ortiz MJ; García-Heredia JM; Carnero A
Cells; 2020 Apr; 9(5):. PubMed ID: 32344898
[TBL] [Abstract][Full Text] [Related]
2. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
Yadav AK; Kumar V; Bailey DB; Jang BC
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
[TBL] [Abstract][Full Text] [Related]
3. Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells.
Lee M; Lee KH; Min A; Kim J; Kim S; Jang H; Lim JM; Kim SH; Ha DH; Jeong WJ; Suh KJ; Yang YW; Kim TY; Oh DY; Bang YJ; Im SA
Cancer Res Treat; 2019 Apr; 51(2):451-463. PubMed ID: 29879757
[TBL] [Abstract][Full Text] [Related]
4. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
5. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
6. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
Chen LS; Yang JY; Liang H; Cortes JE; Gandhi V
Leuk Lymphoma; 2016 Dec; 57(12):2863-2873. PubMed ID: 27054578
[TBL] [Abstract][Full Text] [Related]
7. New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations.
Marques MB; González-Durruthy M; da Silva Nornberg BF; Oliveira BR; Almeida DV; de Souza Votto AP; Marins LF
Curr Top Med Chem; 2019; 19(11):914-926. PubMed ID: 31072293
[TBL] [Abstract][Full Text] [Related]
8. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
Brunen D; de Vries RC; Lieftink C; Beijersbergen RL; Bernards R
Mol Cancer Ther; 2018 Apr; 17(4):849-857. PubMed ID: 29440296
[TBL] [Abstract][Full Text] [Related]
9. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin.
Julson JR; Quinn CH; Nazam N; Bownes LV; Stewart JE; Beierle EA
J Pediatr Surg; 2024 Jul; 59(7):1334-1341. PubMed ID: 38570263
[TBL] [Abstract][Full Text] [Related]
10. Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients.
Zhang RX; Zhou ZG; Lu SX; Lu ZH; Wan DS; Pan ZZ; Wu XJ; Chen G
Sci Rep; 2017 Nov; 7(1):16043. PubMed ID: 29167471
[TBL] [Abstract][Full Text] [Related]
11. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
[TBL] [Abstract][Full Text] [Related]
12. AZD1208, a pan-Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3-L1 adipocytes.
Park YK; Obiang-Obounou BW; Lee KB; Choi JS; Jang BC
J Cell Mol Med; 2018 Apr; 22(4):2488-2497. PubMed ID: 29441719
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
14. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
[TBL] [Abstract][Full Text] [Related]
15. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.
Saw RP; Morgan M; Koorey D; Painter D; Findlay M; Stevens G; Clarke S; Chapuis P; Solomon MJ
Dis Colon Rectum; 2003 Feb; 46(2):192-202. PubMed ID: 12576893
[TBL] [Abstract][Full Text] [Related]
16. PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy.
Anwar A; Lepore C; Czerniecki BJ; Koski GK; Showalter LE
Cell Immunol; 2024; 397-398():104805. PubMed ID: 38244265
[TBL] [Abstract][Full Text] [Related]
17. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
[TBL] [Abstract][Full Text] [Related]
18. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
19. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
Warfel NA; Sainz AG; Song JH; Kraft AS
Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
[TBL] [Abstract][Full Text] [Related]
20. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]